Conditions: Neoplasms, Breast
Keywords: VEGF Tyrosine kinase ErbB2 Her2-neu metastatic breast cancer EGFR ErbB1 bevacizumab lapatinib breast carcinoma breast cancer breast lump breast cancer positive for human epidermal growth factor receptor 2 (HER2) HER2 positive metastatic breast cancer breast cancer progression estrogen-receptor (ER) positive(+) breast cancer Paget's disease
Allocation: NA | Intervention model: 
Enrollment: 52
Healthy volunteers: no

Brief summary:
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.

Detailed description:

Arms:
arm 1: 1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)

Interventions: intervention 1: lapatinib intervention 2: bevacizumab
Intervention descriptions: intervention 1: 1500 mg oral lapatinib (once daily) intervention 2: 10 mg/kg intravenous bevacizumab (every two weeks)

Protocol document: